tiprankstipranks
Pharvaris N.V. (PHVS)
NASDAQ:PHVS
US Market
PHVS
Pharvaris
RESEARCH TOOLSreports
Want to see PHVS full AI Analyst Report?

Pharvaris (PHVS) Stock Forecast & Price Target

174 Followers
See the Price Targets and Ratings of:

PHVS Analyst Ratings

Strong Buy
10Ratings
Strong Buy
9 Buy
1 Hold
0 Sell
Based on 10 analysts giving stock ratings to
Pharvaris
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

PHVS Stock 12 Month Forecast

Average Price Target

$48.04
▲(68.09% Upside)
Based on 10 Wall Street analysts offering 12 month price targets for Pharvaris in the last 3 months. The average price target is $48.04 with a high forecast of $74.00 and a low forecast of $30.40. The average price target represents a 68.09% change from the last price of $28.58.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","30":"$30","45":"$45","60":"$60","75":"$75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":74,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$74.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.04,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$48.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$30.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,30,45,60,75],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2025","6":"Nov<br/>2025","9":"Feb<br/>2026","12":"May<br/>2026","25":"May<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.44,32.86769230769231,36.29538461538462,39.723076923076924,43.150769230769235,46.57846153846154,50.00615384615385,53.43384615384616,56.861538461538466,60.28923076923077,63.71692307692308,67.14461538461539,70.5723076923077,{"y":74,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.44,30.87076923076923,32.30153846153846,33.73230769230769,35.16307692307692,36.59384615384616,38.02461538461539,39.45538461538462,40.886153846153846,42.316923076923075,43.747692307692304,45.178461538461534,46.60923076923076,{"y":48.04,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.44,29.513846153846156,29.587692307692308,29.661538461538463,29.735384615384614,29.80923076923077,29.883076923076924,29.956923076923076,30.03076923076923,30.104615384615386,30.178461538461537,30.252307692307692,30.326153846153844,{"y":30.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.85,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.75,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":27.43,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.45,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.44,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$74.00Average Price Target$48.04Lowest Price Target$30.40
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on PHVS
Maxwell Skor
Morgan Stanley
Morgan Stanley
$41→$30.4
Buy
6.37%
Upside
Reiterated
05/18/26
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)
H.C. Wainwright Analyst forecast on PHVS
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$60
Buy
109.94%
Upside
Reiterated
05/15/26
Pharvaris (PHVS) Receives a Buy from H.C. Wainwright
Bank of America Securities Analyst forecast on PHVS
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$31→$33
Hold
15.47%
Upside
Reiterated
05/14/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pharvaris (NASDAQ: PHVS) and Allogene Therapeutics (NASDAQ: ALLO)
Citizens JMP Analyst forecast on PHVS
Jonathan Wolleben
Citizens JMP
Citizens JMP
$75→$74
Buy
158.92%
Upside
Reiterated
05/13/26
Pharvaris price target lowered to $74 from $75 at CitizensPharvaris price target lowered to $74 from $75 at Citizens
Wedbush Analyst forecast on PHVS
Laura Chico
Wedbush
Wedbush
$42
Buy
46.96%
Upside
Reiterated
05/13/26
Analysts Are Bullish on Top Healthcare Stocks: Kura Oncology (KURA), Pharvaris (PHVS)
Oppenheimer Analyst forecast on PHVS
Jeff Jones
Oppenheimer
Oppenheimer
$50
Buy
74.95%
Upside
Reiterated
05/13/26
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), CytomX Therapeutics (CTMX)
Cantor Fitzgerald Analyst forecast on PHVS
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$46
Buy
60.95%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Pharvaris (NASDAQ: PHVS), Neurogene (NASDAQ: NGNE) and Stereotaxis (NYSE MKT: STXS)
RBC Capital Analyst forecast on PHVS
Nevin Varghese
RBC Capital
RBC Capital
$51
Buy
78.45%
Upside
Reiterated
05/12/26
RBC Capital Reaffirms Their Buy Rating on Pharvaris (PHVS)
JonesTrading Analyst forecast on PHVS
Debanjana Chatterjee
JonesTrading
JonesTrading
$52
Buy
81.95%
Upside
Reiterated
04/15/26
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
Wolfe Research Analyst forecast on PHVS
Andy Chen
Wolfe Research
Wolfe Research
$42
Buy
46.96%
Upside
Initiated
04/08/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and Pharvaris (NASDAQ: PHVS)
Leerink Partners Analyst forecast on PHVS
Joseph Schwartz
Leerink Partners
Leerink Partners
$38
Buy
32.96%
Upside
Reiterated
01/13/26
Pharvaris (PHVS) Receives a Buy from Leerink Partners
Guggenheim Analyst forecast on PHVS
Debjit Chattopadhyay
Guggenheim
Guggenheim
$32→$39
Buy
36.46%
Upside
Reiterated
12/03/25
Analysts Conflicted on These Healthcare Names: Masimo (NASDAQ: MASI), Bristol-Myers Squibb (NYSE: BMY) and Pharvaris (NASDAQ: PHVS)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on PHVS
Maxwell Skor
Morgan Stanley
Morgan Stanley
$41→$30.4
Buy
6.37%
Upside
Reiterated
05/18/26
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), Cardiol Therapeutics (CRDL)
H.C. Wainwright Analyst forecast on PHVS
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$60
Buy
109.94%
Upside
Reiterated
05/15/26
Pharvaris (PHVS) Receives a Buy from H.C. Wainwright
Bank of America Securities Analyst forecast on PHVS
Tazeen Ahmad
Bank of America Securities
Bank of America Securities
$31→$33
Hold
15.47%
Upside
Reiterated
05/14/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Pharvaris (NASDAQ: PHVS) and Allogene Therapeutics (NASDAQ: ALLO)
Citizens JMP Analyst forecast on PHVS
Jonathan Wolleben
Citizens JMP
Citizens JMP
$75→$74
Buy
158.92%
Upside
Reiterated
05/13/26
Pharvaris price target lowered to $74 from $75 at CitizensPharvaris price target lowered to $74 from $75 at Citizens
Wedbush Analyst forecast on PHVS
Laura Chico
Wedbush
Wedbush
$42
Buy
46.96%
Upside
Reiterated
05/13/26
Analysts Are Bullish on Top Healthcare Stocks: Kura Oncology (KURA), Pharvaris (PHVS)
Oppenheimer Analyst forecast on PHVS
Jeff Jones
Oppenheimer
Oppenheimer
$50
Buy
74.95%
Upside
Reiterated
05/13/26
Analysts Are Bullish on Top Healthcare Stocks: Pharvaris (PHVS), CytomX Therapeutics (CTMX)
Cantor Fitzgerald Analyst forecast on PHVS
Steven Seedhouse
Cantor Fitzgerald
Cantor Fitzgerald
$46
Buy
60.95%
Upside
Reiterated
05/12/26
Analysts Offer Insights on Healthcare Companies: Pharvaris (NASDAQ: PHVS), Neurogene (NASDAQ: NGNE) and Stereotaxis (NYSE MKT: STXS)
RBC Capital Analyst forecast on PHVS
Nevin Varghese
RBC Capital
RBC Capital
$51
Buy
78.45%
Upside
Reiterated
05/12/26
RBC Capital Reaffirms Their Buy Rating on Pharvaris (PHVS)
JonesTrading Analyst forecast on PHVS
Debanjana Chatterjee
JonesTrading
JonesTrading
$52
Buy
81.95%
Upside
Reiterated
04/15/26
Pharvaris: Deucrictibant Data, Strengthened HAE Pipeline, and Extended Cash Runway Support Higher $52 DCF-Based Target and Buy Rating
Wolfe Research Analyst forecast on PHVS
Andy Chen
Wolfe Research
Wolfe Research
$42
Buy
46.96%
Upside
Initiated
04/08/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL) and Pharvaris (NASDAQ: PHVS)
Leerink Partners Analyst forecast on PHVS
Joseph Schwartz
Leerink Partners
Leerink Partners
$38
Buy
32.96%
Upside
Reiterated
01/13/26
Pharvaris (PHVS) Receives a Buy from Leerink Partners
Guggenheim Analyst forecast on PHVS
Debjit Chattopadhyay
Guggenheim
Guggenheim
$32→$39
Buy
36.46%
Upside
Reiterated
12/03/25
Analysts Conflicted on These Healthcare Names: Masimo (NASDAQ: MASI), Bristol-Myers Squibb (NYSE: BMY) and Pharvaris (NASDAQ: PHVS)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharvaris

3 Months
Maxwell SkorMorgan Stanley
Success Rate
18/27 ratings generated profit
67%
Average Return
+4.80%
Copying Maxwell Skor's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +4.80% per trade.
1 Year
Maxwell SkorMorgan Stanley
Success Rate
20/27 ratings generated profit
74%
Average Return
+25.83%
Copying Maxwell Skor's trades and holding each position for 1 Year would result in 74.07% of your transactions generating a profit, with an average return of +25.83% per trade.
2 Years
Maxwell SkorMorgan Stanley
Success Rate
26/27 ratings generated profit
96%
Average Return
+46.13%
Copying Maxwell Skor's trades and holding each position for 2 Years would result in 96.30% of your transactions generating a profit, with an average return of +46.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

PHVS Analyst Recommendation Trends

Rating
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Strong Buy
10
10
11
14
17
Buy
9
8
4
4
5
Hold
3
2
1
0
2
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
22
20
16
18
24
In the current month, PHVS has received 22 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. PHVS average Analyst price target in the past 3 months is 48.04.
Each month's total comprises the sum of three months' worth of ratings.

PHVS Financial Forecast

PHVS Earnings Forecast

Next quarter’s earnings estimate for PHVS is -$0.78 with a range of -$0.96 to -$0.68. The previous quarter’s EPS was $0.68. PHVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PHVS has Performed in-line its overall industry.
Next quarter’s earnings estimate for PHVS is -$0.78 with a range of -$0.96 to -$0.68. The previous quarter’s EPS was $0.68. PHVS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year PHVS has Performed in-line its overall industry.
No data currently available

PHVS Sales Forecast

Next quarter’s sales forecast for PHVS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PHVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PHVS has Performed in-line its overall industry.
Next quarter’s sales forecast for PHVS is $0.00 with a range of $0.00 to $0.00. The previous quarter’s sales results were $0.00. PHVS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year PHVS has Performed in-line its overall industry.

PHVS Stock Forecast FAQ

What is PHVS’s average 12-month price target, according to analysts?
Based on analyst ratings, Pharvaris N.V.’s 12-month average price target is 48.04.
    What is PHVS’s upside potential, based on the analysts’ average price target?
    Pharvaris N.V. has 68.09% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is PHVS a Buy, Sell or Hold?
          Pharvaris N.V. has a consensus rating of Strong Buy which is based on 9 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Pharvaris N.V.’s price target?
            The average price target for Pharvaris N.V. is 48.04. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $74.00 ,the lowest forecast is $30.40. The average price target represents 68.09% Increase from the current price of $28.58.
              What do analysts say about Pharvaris N.V.?
              Pharvaris N.V.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 10 Wall Streets Analysts.
                How can I buy shares of PHVS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.